TRK-950

Phase 2Biologic

TToray Industries, Inc

TRK-950 is one of 111 biologic programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Gastric AdenocarcinomaRecruiting

Patients With Advanced Solid TumorsRecruiting

Solid TumorPhase 1

Active, not recruiting

Gastric AdenocarcinomaPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

TRK-950

TToray Industries, Inc

Phase 2

1 2

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 3

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 4

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 5

Carboplatin AUC-5

Merck & Co.

Preclinical

1 6

Soc

Pfizer

Preclinical

1 7

SHR-A2102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Preclinical

1 8

GT201

GGrit Biotechnology

Preclinical

1 9

IL-2

FFate Therapeutics

Preclinical

1 10

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT05423262

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

Completed·TToray Industries, Inc·Phase 1·NCT02990481·38 enrolled

A Study of TRK-950 in Patients With Advanced Solid Tumors

Recruiting·TToray Industries, Inc·Phase 1/2·NCT05423262·49 enrolled

Gastric Adenocarcinoma1 trial

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Recruiting·TToray Industries, Inc·Phase 2·NCT06038578·146 enrolled

Solid Tumor1 trial

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Active, not recruiting·TToray Industries, Inc·Phase 1·NCT03872947·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for TRK-950. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRK-950 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRK-950. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Toray Industries, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: TToray Industries, Inc

TRK-950

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Gastric Adenocarcinoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News